Zenflow, Inc.

About Zenflow, Inc.

Zenflow is a company focused on providing a better treatment for benign prostatic hyperplasia (BPH), or enlarged prostate, which affects many men over 50. Founded with patient comfort as a priority through the Stanford Byers Center for Biodesign innovation program, Zenflow aims to offer a safer, more effective, and patient-friendly solution for BPH, collaborating with top urologists to revolutionize treatment options.

Products & Services

Zenflow Procedure:A clinically evaluated treatment for BPH that offers a gentle approach with no burning, cutting, or piercing of tissue, minimal bleeding, long-term symptom relief, and fast recovery within hours.

Specialties

Benign Prostatic Hyperplasia (BPH) treatment Urology Patient-friendly medical procedures

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 24000000 MR: - FA: 24 million FAN: 24000000	D: 2024-11-18 FD: 2024-11-18	4 investors

Series C Latest

2024-11-18

$24.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Shreya Mehta

CEO & Founder

R

Ronald Jabba

COO

G

Gene Ramirez

CFO

S

Sierra Yearsley

SVP Clinical & Regulatory

J

Jamey Nielsen

VP R&D

A

Andrew Cleeland

Chairman

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

Zenflow, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised